阿奇霉素预防计划阴道分娩女性的脓毒症或死亡
这项多国、安慰剂对照随机试验纳入28周及以上孕周、处于产程中且计划阴道分娩的女性29278例,随机接受单次2 g口服阿奇霉素或安慰剂。母体脓毒症或死亡复合终点发生率阿奇霉素组1.6% vs 安慰剂组2.4%(RR 0.67,95%CI 0.56-0.79,P<0.001),差异主要由脓毒症驱动(1.5% vs 2.3%,RR 0.65,95%CI 0.55-0.77)。死产或新生儿死亡或脓毒症复合终点两组相似(10.5% vs 10.3%,RR 1.02,95%CI 0.95-1.09,P=0.56)。阿奇霉素未增加不良事件发生率。
要点
- 计划阴道分娩产妇产程中单次口服阿奇霉素2 g,母体脓毒症或死亡复合终点1.6% vs 安慰剂2.4%(RR 0.67,95%CI 0.56-0.79,P<0.001)。
- 母体获益主要由脓毒症驱动:阿奇霉素组1.5% vs 安慰剂组2.3%(RR 0.65,95%CI 0.55-0.77)。
- 新生儿复合终点死产或新生儿死亡或脓毒症两组相似:10.5% vs 10.3%(RR 1.02,95%CI 0.95-1.09,P=0.56)。
- neonatal脓毒症9.8% vs 9.6%(RR 1.03,95%CI 0.96-1.10),死产0.4% vs 0.4%(RR 1.06,95%CI 0.74-1.53),出生后4周内新生儿死亡1.5% vs 1.5%(RR 1.03,95%CI 0.86-1.24)。
- 阿奇霉素未增加不良事件发生率;数据和安全监测委员会在中期分析中因母体获益建议提前终止试验。
适用人群与场景
- 28周及以上孕周、处于产程中且计划阴道分娩的女性。
处置流程与药物剂量
- 计划阴道分娩的产妇在产程中接受单次2 g口服阿奇霉素或安慰剂。
研究设计与关键结果
- 多国、安慰剂对照、随机试验,共29278例女性随机分组;主要终点为母体脓毒症或死亡复合终点和死产或新生儿死亡或脓毒症复合终点。
- 母体脓毒症或死亡:阿奇霉素组1.6% vs 安慰剂组2.4%,RR 0.67(95%CI 0.56-0.79),P<0.001。
- 死产或新生儿死亡或脓毒症:阿奇霉素组10.5% vs 安慰剂组10.3%,RR 1.02(95%CI 0.95-1.09),P=0.56。
- 脓毒症:阿奇霉素组1.5% vs 安慰剂组2.3%,RR 0.65(95%CI 0.55-0.77)。
- 任何原因死亡:两组均为0.1%,RR 1.23(95%CI 0.51-2.97)。
- 新生儿脓毒症:阿奇霉素组9.8% vs 安慰剂组9.6%,RR 1.03(95%CI 0.96-1.10)。
- 死产:两组均为0.4%,RR 1.06(95%CI 0.74-1.53);出生后4周内新生儿死亡:两组均为1.5%,RR 1.03(95%CI 0.86-1.24)。
- 阿奇霉素未增加不良事件发生率。
证据类型、等级与局限
- 多国、安慰剂对照、随机试验;中期分析时数据和安全监测委员会因母体获益建议提前终止试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于28周及以上孕周、处于产程中且计划阴道分娩的女性,产程中单次口服阿奇霉素2 g可显著降低母体脓毒症或死亡风险,但对新生儿脓毒症或死亡无明显影响。
指南或共识出处
- A-PLUS试验,ClinicalTrials.gov注册号NCT03871491;由Eunice Kennedy Shriver National Institute of Child Health and Human Development等资助。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The use of azithromycin reduces maternal infection in women during unplanned cesarean delivery, but its effect on those with planned vaginal delivery is unknown. Data are needed on whether an intrapartum oral dose of azithromycin would reduce maternal and offspring sepsis or death.
METHODS: In this multicountry, placebo-controlled, randomized trial, we assigned women who were in labor at 28 weeks' gestation or more and who were planning a vaginal delivery to receive a single 2-g oral dose of azithromycin or placebo. The two primary outcomes were a composite of maternal sepsis or death and a composite of stillbirth or neonatal death or sepsis. During an interim analysis, the data and safety monitoring committee recommended stopping the trial for maternal benefit.
RESULTS: A total of 29,278 women underwent randomization. The incidence of maternal sepsis or death was lower in the azithromycin group than in the placebo group (1.6% vs. 2.4%), with a relative risk of 0.67 (95% confidence interval [CI], 0.56 to 0.79; P<0.001), but the incidence of stillbirth or neonatal death or sepsis was similar (10.5% vs. 10.3%), with a relative risk of 1.02 (95% CI, 0.95 to 1.09; P = 0.56). The difference in the maternal primary outcome appeared to be driven mainly by the incidence of sepsis (1.5% in the azithromycin group and 2.3% in the placebo group), with a relative risk of 0.65 (95% CI, 0.55 to 0.77); the incidence of death from any cause was 0.1% in the two groups (relative risk, 1.23; 95% CI, 0.51 to 2.97). Neonatal sepsis occurred in 9.8% and 9.6% of the infants, respectively (relative risk, 1.03; 95% CI, 0.96 to 1.10). The incidence of stillbirth was 0.4% in the two groups (relative risk, 1.06; 95% CI, 0.74 to 1.53); neonatal death within 4 weeks after birth occurred in 1.5% in both groups (relative risk, 1.03; 95% CI, 0.86 to 1.24). Azithromycin was not associated with a higher incidence in adverse events.
CONCLUSIONS: Among women planning a vaginal delivery, a single oral dose of azithromycin resulted in a significantly lower risk of maternal sepsis or death than placebo but had little effect on newborn sepsis or death. (Funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development and others; A-PLUS ClinicalTrials.gov number, NCT03871491.).
参考来源
- Tita ATN, Carlo WA, McClure EM, et al. Azithromycin to Prevent Sepsis or Death in Women Planning a Vaginal Birth. N Engl J Med. 2023. PMID: 36757318. doi:10.1056/NEJMoa2212111
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。